ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2023
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- Pooled it
- Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- OLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection in Patients With Early Gastric Cancer Without a CurrentJournal of gastric cancer · 2026Article
- Endoscopic Submucosal Dissection for Early Gastric Cancer: From Expanding Utilization to Lifelong Survivorship Care.Journal of gastric cancer · 2026Article
- Optimizing endoscopic detection of early gastric cancer: stratification and preventive strategies for Peri-ESD diagnostic oversights.Frontiers in oncology · 2026Article
- Predictors of the Development of Gastric Cancer in Post-Cancers · 2025Article
- Risk Assessment of Metachronous Gastric Neoplasm after Endoscopic Resection for Early Gastric Cancer According to Age atGut and liver · 2024Article
- Gastric microbiome signature for predicting metachronous recurrence after endoscopic resection of gastric neoplasm.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Early gastric cancer of young patients treated by endoscopic submucosal dissection: focusing on the different characteristics and prognosis of elderly patients.Surgical endoscopy · 2024Article
- Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer.Cancer medicine · 2024Article
- Endoscopic Grading and Sampling of Gastric Precancerous Lesions: A Comprehensive Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Trends and hotspots in gastrointestinal neoplasms risk assessment: A bibliometric analysis from 1984 to 2022.World journal of gastrointestinal oncology · 2024Article
- Impact of endoscopic surveillance on the early diagnosis and endoscopic resection likelihood of gastric cancer.Surgical endoscopy · 2024Article
- Long-term Outcomes of Patients With Early Gastric Cancer Who Had Lateral Resection Margin-Positive Tumors Based on Pathology Following Endoscopic Submucosal Dissection.Journal of gastric cancer · 2024Article
- Gastric cancer incidence based on endoscopic Kyoto classification of gastritis.World journal of gastroenterology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 3 countries.
Funding
Abstract
backgroundMetachronous gastric cancer (MGC) may develop in patients undergoing curative endoscopic submucosal dissection for early gastric cancer. As gastritis and intestinal metaplasia are notable precursors to gastric cancer, we assessed MGC risk using the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM) systems.
methodsThis retrospective cohort study classified the OLGA and OLGIM stages for 916 patients who had undergone endoscopic submucosal dissection for early gastric cancer between 2005 and 2015. MGC development was followed up until 2020 and risk factors were evaluated using the Cox proportional hazards regression analysis.
resultsDuring a median follow-up of 94 months, MGC developed in 120 subjects. OLGA stages II ~ IV were significantly associated with increased MGC risk (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.05-3.19; HR 2.31, 95% CI 1.22-4.38; HR 2.36, 95% CI 1.16-4.78) in multivariable analysis, even after adjusting for the well-known positive predictor of Helicobacter pylori eradication. OLGIM stages II ~ IV also showed significant association (HR 2.86, 95% CI 1.29-6.54; HR 2.94, 95% CI 1.34-6.95; HR 3.64, 95% CI 1.60-8.29). 5-year cumulative incidence increased with each stage. Helicobacter pylori-eradicated patients with OLGIM stages 0 ~ II had significantly less MGC than non-eradicated patients (4.5% vs 11.8%, p = 0.022), which was not observed with OLGIM stages III ~ IV.
conclusionsHigh OLGA and OLGIM stages are independent risk factors for metachronous gastric cancer, with the OLGIM staging system being a better predictor. Patients with OLGIM stages 0 ~ II are a subgroup that may benefit more from Helicobacter pylori eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.